Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR
Top Page
Burning Rock Biotech
(NASDAQ:BNR)
Select Model
Select Model
Rating:57Neutral
Price Target:
$37.00
▲(58.12% Upside)
Action:ReiteratedDate:01/16/26
The score is driven primarily by improving (but still loss-making) financial performance—strong TTM revenue growth and high gross margins offset by negative net margin and ongoing cash burn. Technicals add support due to a strong uptrend and positive MACD, but overbought readings raise near-term risk. Valuation is a headwind given negative earnings (negative P/E) and no dividend yield.
Positive Factors
High gross margins and strong TTM revenue rebound
Sustained high gross margins (~70–73%) combined with a 55.4% TTM revenue rebound indicate robust unit economics in genomic testing. Durable margin profile supports reinvestment in R&D and scale-up, underpinning long-term profitability potential if top-line growth persists.
Negative Factors
Ongoing unprofitable operations and negative cash flow
Despite revenue recovery, the company remains loss-making with TTM net margin around -22.5% and negative operating and free cash flow. Persistent unprofitability stresses the need for sustained improvement in margins or external funding to support operations and long-term growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins and strong TTM revenue rebound
Sustained high gross margins (~70–73%) combined with a 55.4% TTM revenue rebound indicate robust unit economics in genomic testing. Durable margin profile supports reinvestment in R&D and scale-up, underpinning long-term profitability potential if top-line growth persists.
Read all positive factors
Burning Rock Biotech (BNR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$199.18M
Dividend YieldN/A
Average Volume (3M)22.64K
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth5.44%
EPS Growth72.17%
CountryUS
Employees674
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.21
Shares Outstanding9,034,111
10 Day Avg. Volume13,298
30 Day Avg. Volume22,645
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.87
Price to Sales (P/S)0.98
P/FCF Ratio-5.16
Enterprise Value/Market Cap-1.59
Enterprise Value/Revenue-0.59
Enterprise Value/Gross Profit-0.80
Enterprise Value/Ebitda4.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Burning Rock Biotech Business Overview & Revenue Model
Company Description
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Se...
How the Company Makes Money
Burning Rock Biotech generates revenue through a diverse range of business activities. The primary revenue streams include the sale of its genomic testing products and services to hospitals and medical institutions, which utilize these tests for c...
Burning Rock Biotech Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows income generated from each business segment, indicating which areas drive growth and contribute most to the company's top line.
Shows income generated from each business segment, indicating which areas drive growth and contribute most to the company's top line.
Data provided by:
The Fly
The FlyBurning Rock Biotech Earnings Call Summary
Earnings Call Date:May 29, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Jun 02, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive financial turnaround with significant improvements in sales efficiency, profitability, and in-hospital revenue growth. Despite industry challenges, the company demonstrated a strong cash position and strategic adaptability.Positive Updates
Record Low Sales and Marketing Expenses
Achieved sales and marketing expenses as a percentage of revenue at 35%, marking a historic low and the most efficient quarter in recent operating history.
Negative Updates
Industry Operating Environment Challenges
Faced changes in the industry's operating environment starting July last year, impacting revenue distribution and necessitating a transition strategy.
Read all updates
Q1-2024 Updates
Positive
Negative
Record Low Sales and Marketing Expenses
Achieved sales and marketing expenses as a percentage of revenue at 35%, marking a historic low and the most efficient quarter in recent operating history.
Read all positive updates
Company Guidance
During Burning Rock's Q1 2024 earnings call, the company provided optimistic guidance, highlighting significant improvements in their financial metrics. The sales and marketing expenses were reduced to 35% of revenue, marking a historic efficiency level, which underpins their operating profitability. The company's gross profit minus SG&A expenses turned positive again in Q1 2024, after a challenging Q3 and Q4 in 2023. Burning Rock ended the quarter with an RMB 573 million cash balance and projected a cash outflow between RMB 150 million to RMB 200 million for 2024. They also noted a successful transition in their revenue model, with more income now coming from in-hospital services than from Central Labs, contributing to a 4% increase in overall revenue quarter-over-quarter. The company aims to maintain positive non-GAAP gross profit minus SG&A for the entirety of 2024 and anticipates further cash flow improvements into 2025.Burning Rock Biotech Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 539.27M | 515.82M | 537.43M | 563.24M | 507.86M | 429.90M |
| Gross Profit | 393.77M | 362.40M | 363.23M | 380.04M | 364.15M | 313.92M |
| EBITDA | -63.91M | -270.23M | -517.90M | -856.31M | -746.50M | -373.26M |
| Net Income | -121.25M | -346.63M | -653.69M | -971.23M | -796.70M | -407.24M |
Balance Sheet | ||||||
| Total Assets | 812.17M | 885.30M | 1.04B | 1.59B | 2.28B | 2.66B |
| Cash, Cash Equivalents and Short-Term Investments | 463.99M | 519.85M | 615.10M | 905.45M | 1.50B | 2.26B |
| Total Debt | 33.18M | 52.32M | 12.32M | 50.79M | 86.69M | 46.88M |
| Total Liabilities | 262.59M | 304.48M | 271.59M | 429.13M | 433.28M | 242.02M |
| Stockholders Equity | 549.58M | 580.83M | 768.41M | 1.16B | 1.85B | 2.42B |
Cash Flow | ||||||
| Free Cash Flow | -37.84M | -98.24M | -265.17M | -518.84M | -691.33M | -153.08M |
| Operating Cash Flow | -32.42M | -92.26M | -255.78M | -456.81M | -477.89M | -73.54M |
| Investing Cash Flow | -4.88M | -4.41M | -9.30M | -7.46M | 81.70M | -109.31M |
| Financing Cash Flow | 1.93M | -72.00K | -48.83M | -86.24M | -52.90M | 2.17B |
Burning Rock Biotech Technical Analysis
Negative
23.40
Price Trends
27.37
Negative
22.68
Negative
14.95
Positive
Market Momentum
-2.18
Negative
39.30
Neutral
57.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNR, the sentiment is Negative. The current price of 23.4 is above the 20-day moving average (MA) of 20.95, below the 50-day MA of 27.37, and above the 200-day MA of 14.95, indicating a neutral trend. The MACD of -2.18 indicates Negative momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 57.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNR.
Burning Rock Biotech Risk Analysis
Burning Rock Biotech disclosed 88 risk factors in its most recent earnings report. Burning Rock Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Burning Rock Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $199.18M | -2.82 | -21.40% | ― | 5.44% | 72.17% | |
56 Neutral | $143.93M | -1.46 | -302.55% | ― | 22.29% | 31.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.76M | -0.32 | -56.22% | ― | -13.84% | 88.80% | |
48 Neutral | $77.90M | -4.40 | -47.69% | ― | 1.06% | 22.41% | |
47 Neutral | $26.16M | -3.41 | 76.82% | ― | 14.48% | 36.83% | |
46 Neutral | $11.43M | -0.95 | 80.66% | ― | -4.35% | -6.31% |
* Healthcare Sector Average
BNR
Burning Rock Biotech
18.50
13.98
309.29%
TRIB
Trinity Biotech
0.61
-0.03
-4.37%
VNRX
VolitionRX
0.19
-0.36
-64.91%
BNGO
BioNano Genomics
1.15
-1.75
-60.34%
BDSX
Biodesix
14.60
1.20
8.96%
SERA
Sera Prognostics
1.99
-1.55
-43.79%
Burning Rock Biotech Corporate Events
Burning Rock Biotech Shareholders Approve All Resolutions at 2025 AGM
Dec 23, 2025
On December 23, 2025, Burning Rock Biotech announced that all shareholder resolutions proposed at its 2025 annual general meeting held the same day were approved, reinforcing continuity in both its governance and audit oversight. Shareholders rati...
Burning Rock Biotech Schedules 2025 AGM for December 23
Dec 1, 2025
Burning Rock Biotech Limited announced that its 2025 Annual General Meeting (AGM) will be held on December 23, 2025, in Shanghai. The AGM will address proposals such as the ratification of Ernst Young Hua Ming LLP as auditors, the re-election of ...
Burning Rock Biotech Announces Q3 2025 Financial Results with Revenue Growth
Nov 20, 2025
Burning Rock Biotech reported its financial results for the third quarter of 2025, highlighting a 2.3% increase in total revenues compared to the same period in 2024. The company experienced a significant increase in revenue from pharma research a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.